Dobutamine Infusion Rate for 250 mg Vial
For a 70-kg adult, start dobutamine at 2.5 μg/kg/min (175 μg/min or 10.5 mg/hour), which can be titrated up to 2-20 μg/kg/min based on hemodynamic response.
Preparation and Concentration
The 250 mg vial must be diluted to at least 50 mL using compatible IV solutions (5% dextrose, normal saline, or other approved diluents) 1. Common concentrations used are:
- 500 μg/mL (250 mg in 500 mL)
- 1,000 μg/mL (250 mg in 250 mL)
- 2,000 μg/mL (250 mg in 125 mL)
- Up to 5,000 μg/mL (250 mg in 50 mL) has been safely administered 1
Dosing Algorithm
Starting Dose
Begin at 0.5-1.0 μg/kg/min and titrate every few minutes based on response 1. However, most guidelines recommend starting at 2.5 μg/kg/min for patients with heart failure or low cardiac output 2, 3, 4.
For a 70-kg patient starting at 2.5 μg/kg/min:
- Using 1,000 μg/mL concentration: 10.5 mL/hour
- Using 500 μg/mL concentration: 21 mL/hour
Titration Strategy
Double the dose every 15 minutes according to response or tolerability, with dose titration typically limited by excessive tachycardia, arrhythmias, or ischemia 2. The usual therapeutic range is 2-20 μg/kg/min, though doses up to 40 μg/kg/min have occasionally been required 1.
For a 70-kg patient, common dose escalation:
- 2.5 μg/kg/min = 175 μg/min (10.5 mg/hour)
- 5 μg/kg/min = 350 μg/min (21 mg/hour)
- 10 μg/kg/min = 700 μg/min (42 mg/hour)
- 20 μg/kg/min = 1,400 μg/min (84 mg/hour)
Clinical Context-Specific Dosing
Acute Heart Failure with Hypoperfusion: Start at 2.5 μg/kg/min, doubling every 15 minutes up to 10-20 μg/kg/min 2. A dose >20 μg/kg/min is rarely needed 2.
Post-Cardiac Arrest/Cardiogenic Shock: The standard range is 5-10 μg/kg/min 5. For renal hypoperfusion, consider dopamine instead; if pulmonary congestion dominates, dobutamine is preferred starting at 2.5 μg/kg/min and increasing gradually at 5-10 minute intervals up to 10 μg/kg/min 3.
Patients on Beta-Blockers: May require doses up to 20 μg/kg/min to overcome beta-blockade 4. Consider levosimendan or phosphodiesterase inhibitors as alternatives if dobutamine response is inadequate 2.
Monitoring Requirements
Monitor continuously during infusion 1:
- Systemic blood pressure (invasively or non-invasively)
- Heart rate and rhythm (ECG telemetry mandatory)
- Urine output (target >100 mL/hour in first 2 hours for acute heart failure) 2
- Cardiac output, central venous pressure, and/or pulmonary capillary wedge pressure when possible 1
- Signs of hypoperfusion (cold skin, confusion, oliguria, myocardial ischemia)
Critical Caveats
Avoid in:
- Systolic blood pressure <85-90 mmHg without concurrent vasopressor support 2
- Severe aortic stenosis
- Hypertrophic obstructive cardiomyopathy
Common adverse effects limiting titration:
- Tachycardia (most common dose-limiting factor)
- Ventricular and atrial arrhythmias 2, 4
- Myocardial ischemia
- Hypotension (due to beta-2 vasodilatory effects) 5, 2
Weaning: Gradual tapering is essential—decrease by steps of 2 μg/kg/min while simultaneously optimizing oral therapy 4. Abrupt discontinuation can cause hemodynamic deterioration.
Duration: Use for the shortest duration possible. Prolonged inotrope use is associated with increased mortality 2, 4. Withdraw as soon as adequate organ perfusion is restored and/or congestion reduced 4.
Practical Infusion Rates
Using the FDA-approved dosing table for a 70-kg patient with 1,000 μg/mL concentration 1:
| Dose (μg/kg/min) | Infusion Rate (mL/hour) |
|---|---|
| 2.5 | 10.5 |
| 5 | 21 |
| 7.5 | 31.5 |
| 10 | 42 |
| 15 | 63 |
| 20 | 84 |
The solution should be used within 24 hours of preparation 1.